Sab Biotherapeutics, Inc. · NASDAQ:SABS
Sab Biotherapeutics — BIO CEO and Investor Conference 2023
17 slides from Sab Biotherapeutics's conference presentation, Feb 7, 2023
Slide 1: Next Generation Biologics in Immunology
Exhibit 99.1 Heuy BIOTHERAPEUTICS Next Generation Biologics in Immunology Solution for Complex Diseases BIO CEO and Investor Conference| February 2023 Eddie J. Sullivan, PhD President and CEO
Slide 2: Forward-Looking Statements
Forward-Looking Statements “The material inthis presentation has been prepared by SAB Biotherapeutcs Inc. ("SAB") and i general background Information about SAB's activities current a5 ofthe date ofthis presentation. This information i ivenin summary form and inet Intended tobe complete. Informatio
Slide 3: SAB Biotherapeutics Fact Sheet
SAB Biotherapeutics Fact Sheet ©b | | aif 2 90 al Yearsorless from Anti-infective Percent success Subjectstreated fi Assetstodatethat [| Onlycompany to concepttoIND ff assetswith proven [fl rate from concept with SAB lostefficacyto ff produce unlimited filing efficacy in toINDand beyond [J therapeut
Slide 4: Demonstrated as a Novel Discovery Platform for Human Monoclonal and Polyclonal Antibodies
Demonstrated as a Novel Discovery Platform for Human Monoclonal and \. * Polyclonal Antibodies Telomere Avidity matured PBMCs available for screening eer LS BY iS ee IgK HiChar.2 sittencace: kmcteenica’ “WE, tewrmecny fowsen Downstream Processes: Centromere + Antigen specific Fluorescence Activated
Slide 5: SAB Human Polyclonal Antibodies: Next Generation of Biologics
SAB Human Polyclonal Antibodies: Next Generation of Biologics Key Product Differentiators vs Monoclonal Antibodies: ‘© Multi-target capability in a single therapeutic Natural multi-epitope targeted pb selected and produced in Ability to target multiple disease pathways at once increase potential for
Slide 6: Biologic Pipeline with Broad Polyclonal Therapeutic Reach
Biologic Pipeline with Broad Polyclonal Therapeutic Reach R&D PIPELINE isa ed Waa iat aera a sne-15 cLosrRiiones FRCL one OR APLASTIC ANEMIA ANTHOIOTYPE _ SYSTEMICLUPUS ERYTHEMATOSUS, SERIES TYPE DIABETES, RHEUMATOID ARTHRITIS. ae = a © 2023 SAB BIOTHERAPEUTICS, IN BIOTHERAPEUTICS
Slide 7: Clinical Development Programs: Asset Progress
Clinical Development Programs: Asset Progress topline A ‘TSAB-195 Phase 3 FPI **5A8-142 Phase 1/POBA ongoing ‘sA8-195 Phase 2 topline ‘sAB-176 Phase 3 FPI ‘TSAB-142 IND (T10) ‘Tsa8-142 Phase 1/POBA FPI 'SAB-195 IND {CO}, targeting #2 fl 75A8-195 Phase 1/POBA FP .023-H1 2024) ‘'saB-176 2023-2024 flu
Slide 8: Only SAB-176 Provides Potential for "EVERGREEN" Influenza Biologic with Low Risk of Escape Mutants
Only SAB-176 Provides Potential for “EVERGREEN” Influenza Biologic with Low Risk of Escape Mutants First-in-class fully-human polyclonal antibody treatment aimed to provide superior long-lasting efficacy for prophylaxis and management of influenza in patients at high-risk Broadly Balorave | oeutratc
Slide 9: Established Proof-of-Concept for SAB-176: Met Primary Endpoint of Viral Load Reduction
Established Proof-of-Concept for SAB-176: Met Primary Endpoint of Viral Load Reduction in Phase 2a Challenge Study Achieved Statistically Significant SAB-176 Achieved Statistically Significant ‘SAB-176 Shortened Time of Viral Shedd (p= 0.026) Reduction in Viral Load (p= 0.013) Improvement in Symptom
Slide 10: Only SAB-195 Can Target Multiple C. diff Antigens and Toxins in One Therapeutic
Only SAB-195 Can Target Multiple C. diff Antigens and Toxins in One Therapeutic first.in-ctass fully-human polyclonal antibody treatment with dual mechanism of action designed to treat severe CDI and reduce CDI recurrenc Mode of ction (MoA) Targets: + Cait spores cr bacteria + Toxin + Toxins + Binar
Slide 11: SAB-195 Preclinical Data
SAB-195 Preclinical Data ms Tc bovine Immunized with Antigen Fusion Proteins Constructed from Receptor Binding Domain of C. diff Toxin A (Ted), C. diff Toxin B (TedB)(630) and (TcdB)(027) and Binary Toxin (CDT) B C. difficile strain 630 c C. difficile B1/NAP 1/027 100- 100: aan r vats i Bl} at TS g
Slide 12: SAB-142: Only Fully-Human Polyclonal Anti-Thymocyte Immunoglobulin
SAB-142: Only Fully-Human Polyclonal Anti-Thymocyte Immunoglobulin 2 First-in-class fully human polyclonal antibody treatment aimed to provide superior efficacy for delaying onset of clinical Stage 3 Type 1 Diabetes (T10) Teplizumab Low Dose ATS Mechanism of Action (MoA): + Anti-CD3 i) 13) 13] + Ant
Slide 13: SAB-142: GLP Tox Study Results Enable IND Submission
SAB-142: GLP Tox Study Results Enable IND Submission Objectives: © Determine the potential toxicity of SAB-142 vs. an anti-thymocyte globulin (ATG) when given by single intravenous infusion to non- human primates © Characterize mechanism of action, toxicokinetic & immunogenicity profile of SAB-142 R
Slide 14: DiversitAb Platform Anti-ID Proof of Principle in Autoimmune Disease
DiversitAb™ Platform Anti-ID Proof of Principle in Autoimmune Disease 1 ee capabil ty in a single therapeutic pAbs generated by hyperimmunization with lity to target multiple autoantibodies at once increase potential for superior efficacy selected mabe shoved ingto the variable region and blocked in
Slide 15: DiversitAb Anti-Variable/Anti-ID hpAbs are Specific to the Variable Region
DiversitAb™ Anti-Variable/Anti-ID hpAbs are Specificto the Variable cs Region 100X Excess Competitive Ab/Fragments Tebovine sample Pre-immunization 4 ‘mABGL ‘MAbG4-like ‘MABGL-like (TeBovine Antigen) _ Fab Fragment FcFragment ‘mAbGL-like framework V3higG VahigG 48 VShigG: Tz Tebovine sample 100X Exc
Slide 16: Comparison of Treatments for Systemic Lupus Erythematosus (SLE)
Comparison of Treatments for System Lupus Erythematosus (SLE) a6 Immunosuppressive ; Therapies preva SAB's Anti1D (i.e,, mAb Belimumab Polyclonal menor Antibodies (i.e.,anti-malarial drugs, conticost ‘Mechanism of Action (MoA): + General Immune Suppression + Suppression ofall 8 cells + Suppression/e
Slide 17: Summary
Summary + DiversitAb™ Platform: Innovative Diversitb™ platform produces a new class of targeted fully-human, highly-potent polyclonal antibodies, with a broad efficacy spectrum in a broad range of indications. + Platformis well-positioned to address complex diseases with targeting multiple epitopes
SAB Biotherapeutics — BIO CEO and Investor Conference 2023 on 6ix